37 results
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
of POINT’s business.
Potential Conflicts of Interest. The POINT Board considered the potential conflict of interest created by the fact that POINT’s executive
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
or potential conflict of interest between their work for us and their work for another entity arises, we may lose their services. These factors could
8-K
EX-99.1
u3jwec
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
424B3
vxuil c7z
11 Jul 22
Prospectus supplement
4:32pm
POS AM
gx4dv5zuhw1wky
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
424B3
nelj4swab2
31 Mar 22
Prospectus supplement
11:42am
POS AM
nst6fg2abwkulm2e
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
qwpc4
5 Aug 21
Prospectus supplement
4:26pm
8-K
EX-10.2
4va1fjfpvgnte6 tjo0
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
8-K
EX-10.18
4f0rn8lp
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
424B3
mtxij7r nfa
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
EX-10.18
5hz3trwtrfuwfve05
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
h1kukvoj2i3qme ovif9
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm